If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML) and what monitoring is available. Decades of clinical research have established that regular follow-up tests—including MRI scans and JC virus antibody testing—are essential for early detection. This guide explains the standard monitoring protocols and what they mean for your long-term outlook.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the association and the need for careful patient monitoring. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into the central nervous system. This immunosuppressive effect reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance against the JC virus. In immunocompromised individuals, the JC virus can reactivate and infect oligodendrocytes, leading to demyelination and the characteristic brain lesions of PML. The FDA-approved prescribing information identifies three primary risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are cumulative, meaning that patients with multiple risk factors face a higher likelihood of developing PML.
Clinical presentation of PML is variable but typically includes subacute neurological deficits such as progressive weakness, cognitive decline, visual disturbances, and gait abnormalities. Diagnosis relies on brain magnetic resonance imaging showing multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The FDA adverse event reporting system (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may overlap with PML or other complications. The boxed warning mandates that healthcare professionals 'monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML' and that 'TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The FDA boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients and prescribers fully understand the magnitude of the risk, particularly the cumulative effect of treatment duration and prior immunosuppressant use. For patients who develop PML, the timeline between exposure and documented harm is critical. PML can occur months to years after starting Tysabri, with risk increasing after two years of therapy. This latency period complicates the attribution of harm and may affect legal considerations, such as the statute of limitations for filing a claim. For affected patients in Florida, attorney-related considerations are important. The statute of limitations for personal injury claims in Florida generally allows four years from the date the injury is discovered or should have been discovered. Given that PML symptoms may be subtle initially and diagnosis can be delayed, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. Patients who developed PML after prolonged Tysabri use should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances. Legal claims may focus on whether the manufacturer provided adequate warnings about PML risk, including the need for regular monitoring and the significance of anti-JCV antibody status. The FDA's boxed warning and the TOUCH program are evidence of regulatory oversight, but plaintiffs may argue that these measures were insufficient to prevent harm in their case.
In summary, the evidence clearly establishes that Tysabri increases the risk of PML, a devastating condition with high morbidity and mortality. The drug's pharmacology, risk factors, and clinical presentation are well-documented in FDA-approved labeling and adverse event data. For patients in Florida who have suffered PML after Tysabri use, understanding the statute of limitations and seeking legal counsel promptly is essential. The timeline between exposure and harm, combined with the adequacy of warnings, forms the basis for potential legal action. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury is discovered or should have been discovered. For Tysabri-related PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. It is crucial to consult with an attorney promptly to evaluate your specific case.
The FDA-approved prescribing information identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are cumulative, increasing the likelihood of PML when multiple are present (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.